“Contribute to medical care by developing, manufacturing and delivering essential medicines that other companies do not pursue.” Nobelpharma was created in 2003 based on this mission.

During the 23 years since our founding, we have gained numerous approvals—for 19 new ethical drugs, 7 additional indication, and 1 new medical device—and received 19 orphan drug/medical device designations as well as 2 SAKIGAKE (forerunner) designations (RAPALIMUS^® GEL and TITANBRIDGE^®). We have also advanced overseas since 2016, receiving 1 orphan designation each in the US and Europe in 2017 as well as the approval in March 2022 in the US by the U.S. Food and Drug Administration (FDA) for “HYFTOR^™ (sirolimus topical gel)” for the indication of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and children 6 years of age or older which was launched in August of that year. HYFTOR was also approved in 2023 in China by National Medical Products Administration in March, in EU by European Commission in May, and in England in September, and launched in EU and England in October of that year and in China in January 2024. In China, we received an approval in February 2024 for Nobelzin^® (for Wilsonʼs disease) which becomes the second product overseas. While EU and China businesses have not yet contributed to the companyʼs profit, US business has become profitable in 2024.

Nobelpharma was started with only 6 staff members. Now, Nobelpharma has developed into a company with 368 employees (as of December 2024), carrying out research and development with our primary code of conduct, “When in doubt, the patient benefit takes priority.”

Meanwhile, we booked our first sales in 2008, and after turned positive in 2011, we have seen 13 straight years of profits up to 2023. Thankfully in 2023, we have achieved sales of 19 billion yen with net income of 2 billion yen. In 2024 we had to face decrease of sales and operating profit due to the impact of generic products. Including the recognition of non-operating losses related to the devaluation of loans to and investment in our subsidiaries in US and China we posted net loss of 2.2 billion yen in 2024, but we expect to regain profitability in 2025.

With that being said, our purpose is not pursuit of revenue and profit itself; we consider these to be merely the fruits of achieving our mission and the means to achieve our mission.

Nobelpharma is an unlisted company with three corporate shareholders. Fortunately, each of our shareholders identifies with our thoughts behind Nobelpharma's mission, management policies, and code of conduct. They show their understanding over our prior investment in our research and development of new drugs and medical devices and in our overseas expansion (to China, the US, and Europe), without being excessively concerned with immediate profit.

On the other hand, the new drugs and medical devices industry is facing a difficult time. This is mainly because the research and development of new drugs and medical devices has become more challenging than before, and because growing social criticism towards escalation of medical expenses has led to even tougher drug pricing for new drugs and medical devices.

However, our founding mission remains unchanged in all times of history as we are confident that it continues to have major social significance. Issai Sato, a Confucian scholar born in the late eighteenth century, left behind the words: "I walk in the darkness of the night with a lamp in my hand. I must not worry about the darkness but trust the lamp as my guide." Having Nobelpharma's founding mission and our abovementioned code of conduct as our “lamp,” we are even more committed to the further development of our business facing up to these difficult times.